Influence of absorption promoters on pulmonary insulin bioactivity
- PMID: 12916897
- PMCID: PMC2750593
- DOI: 10.1208/pt040315
Influence of absorption promoters on pulmonary insulin bioactivity
Abstract
The purpose of this research was to enhance the bioactivity of insulin by the pulmonary route using a combination of absorption promoters. Aliquots (100 microL) containing 1.0 IU/kg to 7.0 IU/kg doses of porcine insulin solutions with different classes of absorption promoters and combinations of these at 3 concentration levels were instilled intratracheally to the anesthetized rats. Blood concentrations of glucose were measured at specific time points. Out of 3 concentration levels of each of the absorption promoters used, the formulations having the least concentration with the maximum percentage of blood glucose reduction were selected for combining absorption promoters, and their pharmacodynamic parameters related to insulin absorption were determined. The pharmacodynamics of porcine insulin following subcutaneous administration of increasing doses were also determined. The relative pulmonary bioactivity of insulin in phosphate buffer pH 7.4 and citrate buffer pH 3.5 was 11.36% +/- 1.27% and 43.20% +/- 2.48%, respectively, compared to subcutaneous administration. Relative pulmonary bioactivity of 155.60% +/- 5.19% was obtained when oleic acid sodium salt, sodium tauroglycocholate, bestatin, and chymostatin were coadministered in citrate buffer pH 3.5 solution. However, only 61.91% +/- 3.21, 67.09% +/- 3.23%, 67.24% +/- 2.11%, and 69.84% +/- 3.02% were obtained, respectively, upon incorporation of these absorption promoters individually. Absorption promoters in combination have significant potential for increasing the pulmonary bioactivity of insulin. These studies support the argument that pulmonary administration of insulin is a viable alternative to subcutaneous administration for diabetic patients.
Similar articles
-
Pulmonary absorption enhancement of salmon calcitonin.J Drug Target. 2004 Apr;12(3):135-44. doi: 10.1080/1061186042000223644. J Drug Target. 2004. PMID: 15203892
-
Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats.Pharm Res. 2001 Dec;18(12):1677-84. doi: 10.1023/a:1013362227548. Pharm Res. 2001. PMID: 11785686
-
Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):485-500. doi: 10.1007/s10928-005-0008-4. J Pharmacokinet Pharmacodyn. 2005. PMID: 16284921
-
Clinical pharmacokinetics and pharmacodynamics of insulin aspart.Clin Pharmacokinet. 2001;40(9):641-59. doi: 10.2165/00003088-200140090-00002. Clin Pharmacokinet. 2001. PMID: 11605714 Review.
-
Absorption kinetics of insulin after subcutaneous administration.Eur J Pharm Sci. 2009 Jan 31;36(1):78-90. doi: 10.1016/j.ejps.2008.10.018. Epub 2008 Nov 5. Eur J Pharm Sci. 2009. PMID: 19028573 Review.
Cited by
-
Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin.Mol Pharm. 2009 Mar-Apr;6(2):492-503. doi: 10.1021/mp800174g. Mol Pharm. 2009. PMID: 19228019 Free PMC article.
References
-
- Haeckel S, Sachse S, Albayrak C, Müller RH. Preparation and characterization of insulin-loaded microcapsules produced by the induced phase separation method. In: Proceedings of the World Meeting, 1998 APGI/APV, Paris.
-
- Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv. 1995;2:1–20. doi: 10.3109/10717549509031346. - DOI
-
- Stanley SD. Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm Sci Tech Today. 1999;12:450–459. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical